Clinical trials: Levodopa
Depression
Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa
The purpose of this study is to learn more about the changes that happen in the brain and the body when a person is depressed. This study will determine if the level of inflammation in the body is related to symptoms of…
- Trial name
- NCT02513485
- Testing
- Levodopa+carbidopa
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Emory University
Dyskinesia, Drug-Induced, Parkinson Disease
rTMS as an Intervention for Levodopa-induced Dyskinesia
The proposed study investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for levodopa-induced dyskinesia (LID) in Parkinson's Disease (PD).
- Trial name
- ADAPT-LIDI (NCT06570824)
- Testing
- active TMS
- Where
- Denmark
- Volunteers
- 68 people
- Sponsor
- Danish Research Centre for Magnetic Resonance
Parkinson's Disease
A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients
An open-label randomized study to evaluate the Safety, Tolerability, and PK of Low and High single doses of ND0612 (i.e. LD/CD ratio 60/7.5 mg/mL and 60/14 mg/mL), as well as the combination with oral Entacapone (concomitant…
- Trial name
- NCT02096601
- Testing
- LD/CD SC solution, Entacapone
- Where
- 2 sites in Israel
- Volunteers
- 16 people
- Sponsor
- NeuroDerm Ltd.
Parkinson's Disease, L-dopa Induced Dyskinesia
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients
This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.
- Trial name
- NCT00888004
- Testing
- AFQ056
- Where
- 5 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Novartis
Advanced Parkinson's Disease
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.
- Trial name
- NCT00660387
- Testing
- Levodopa carbidopa intestinal gel (LCIG), Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets, CADD-Legacy® 1400 ambulatory infusion pump
- Where
- 14 sites in United States, New Zealand
- Volunteers
- 35 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Impulse Control Disorder
Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa
The purpose of this study is to see whether the ICDs(Impulse Control Disorder) are improved and neuropsychiatric traits related to ICD are changed or not when switching dopamine agonist to levodopa/carbidopa in patients with…
- Trial name
- REIN-PD (NCT01683253)
- Testing
- Levodopa/Carbidopa(200mg/50mg), Dopaminergic Agonists
- Where
- 5 sites in South Korea
- Volunteers
- 150 people
- Sponsor
- Sandoz
Parkinson Disease
Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease
To investigate the efficacy and the safety of ropinirole PR/XR tablets to ropinirole immediate release (IR) tablets with advanced Parkinson's disease in conjunction with L-dopa in a double-blind, parallel group comparison study.
- Trial name
- NCT00823836
- Testing
- ropinirole PR/XR, ropinirole IR
- Where
- 54 sites in Japan
- Volunteers
- 302 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease
eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.
This is a randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study in Parkinson's disease (PD) patients to evaluate the add-on efficacy of opicapone 50 mg or an extra dose of levodopa…
- Trial name
- ADOPTION (NCT04990284)
- Testing
- Opicapone, L-DOPA/DDCI
- Where
- 25 sites in Germany, Italy and 3 more
- Volunteers
- 106 people
- Sponsor
- Bial - Portela C S.A.
Idiopathic Parkinson's Disease
The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease
Levodopa and non-ergot dopaminergic agonists such as pramipexole are both recommended as the first-line symptomatic treatment for early untreated Parkinson's disease (PD), previous clinical trial indicated that initial…
- Trial name
- NCT01470859
- Testing
- pramipexole, Sinemet CR
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huashan Hospital
Parkinson Disease
Continuous Theta Burst Stimulation as Potential Biomarker of Levodopa-induced Dyskinesias in Parkinson's Disease
The primary endpoint of the study is to identify a neurophysiological biomarker (absence of synaptic depotentiation at primary motor cortex , measured as change in the amplitude of motor evoked potentials recorded at the dorsal…
- Trial name
- NCT05795088
- Testing
- Continuous theta burst stimulation
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Parkinson's Disease
Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy
The purpose of this study is to evaluate the efficacy of KW-6500 versus placebo when administered as a subcutaneous injection at the individualized maintenance dose level in an OFF state in Parkinson's disease patients with motor…
- Trial name
- NCT00610103
- Testing
- apomorphine hydrochloride
- Where
- 4 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson Disease
Personality, as a Predictive Factor of Therapeutic Response on Quality of Life After Continuous Perfusion of Dopaminergic Drugs, in Parkinson's Disease
The aim of the study is to evaluate if patients' personality could be considerate as predictive factor of quality of life after the establishment of continuous infusion of dopaminergic treatments to observe if there are…
- Trial name
- PSYCHO-PERF (NCT03793491)
- Testing
- TCI scale, PDQ-39 scale
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Toulouse
Parkinson Disease
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
- Trial name
- NCT06765668
- Testing
- CREXONT ER
- Where
- 27 sites in United States
- Volunteers
- 220 people
- Sponsor
- Impax Laboratories, LLC
Dyskinesias, Parkinson Disease
Effects of Talampanel on Patients With Advanced Parkinson's Disease
The purpose of this research study is to test the safety and effectiveness of the study drug, Talampanel, when used to treat patients with involuntary movements known as dyskinesias, as a result of treatment to Parkinson's…
- Conditions
- Dyskinesias, Parkinson Disease, Movement Disorders
- Trial name
- NCT00036296
- Testing
- talampanel
- Volunteers
- 22 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson's Disease
A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
To establish the efficacy of 10, 20 and 40 mg/d dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
- Trial name
- NCT00199420
- Testing
- Istradefylline (KW-6002)
- Where
- 2 sites in United States
- Volunteers
- 580 people
- Sponsor
- Kyowa Kirin, Inc.
Parkinson's Disease
A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067
The purpose of this study is to investigate the effect of BIA 9-1067 on the levodopa pharmacokinetics when administered in combination with immediate release levodopa/carbidopa or levodopa/benserazide in Parkinson's Disease (PD)…
- Trial name
- NCT01568034
- Testing
- BIA 9-1067, Levodopa/Carbidopa, Levodopa/Benzerazide
- Where
- 3 sites in Portugal, Romania and 1 more
- Volunteers
- 10 people
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Levodopa Concentration Profile With Stalevo 75/125 mg
The purpose of this study is to confirm that the dose levels and dosing frequency utilising the new Stalevo strengths would result into more stable levodopa plasma levels.
- Trial name
- NEWSTA (NCT01070628)
- Testing
- Stalevo (levodopa/ carbidopa/ entacapone), Sinemet (levodopa/carbidopa)
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson Disease
A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease
This is a double blind, fixed dose, parallel group study to characterize the dose response of ropinirole PR as adjunctive therapy to L-dopa in patients with late stage Parkinson's disease.
- Trial name
- TANDEM-569 (NCT01494532)
- Testing
- ropinirole/L-dopa
- Where
- 52 sites in United States, Argentina and 5 more
- Volunteers
- 352 people
- Sponsor
- GlaxoSmithKline
Fasted State
Pharmacokinetic Study With Levodopa-carbidopa Fixed-dose Products in Healthy Subjects After Oral Administration
The study is carried-out to describe and compare the plasma pharmacokinetics of levodopa and carbidopa after oral single-dose administration of 100 mg levodopa plus 25 mg carbidopa by means two fixed combination products (test…
- Trial name
- LCD18K (NCT02116465)
- Testing
- Levodopa Carbidopa immediate release tablets
- Where
- Bulgaria
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Desitin Arzneimittel GmbH
Parkinson's Disease
A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants
The purpose of this study is to evaluate long-term safety of TVP-1012 (1 mg/day) with levodopa in Japanese participants with Parkinson's disease.
- Trial name
- NCT02337764
- Testing
- TVP-1012 1mg
- Where
- 24 sites in Japan
- Volunteers
- 222 people
- Sponsor
- Takeda